Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126500 | 0.85 | CYP3A4 (0.80) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL1126417 | 0.78 | L3MBTL1 (0.81) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL1126545 | 0.78 | L3MBTL1 (1.00) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL1126436 | 0.78 | L3MBTL1 (0.81) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL1127288 | 0.77 | L3MBTL1 (0.66) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL1126369 | 0.76 | L3MBTL1 (0.80) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL8875381 | 0.71 | MAPT (0.58) | MAPTLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1126453 | 0.66 | MAPT (0.42) | L3MBTL1MAPTLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL9410623 | 0.64 | NPC1 (0.56) | L3MBTL1MAPTLMNASMN1; SMN2TDP1 | |
| SCHEMBL29167150 | 0.63 | AXL (0.68) | MAPTLMNACYP3A4SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | claimed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | claimed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | claimed |
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | L3MBTL1 1045/4885MAPT 1696/4885LMNA 3641/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | L3MBTL1 1045/4885MAPT 1696/4885LMNA 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.